Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

United medicinal composition used for treating urogenital system and lower urinary tract diseases

A composition and drug technology, applied in the field of genitourinary system and lower urinary tract diseases, can solve problems such as potassium deficiency

Inactive Publication Date: 2010-02-17
许洁
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

6. Severe potassium deficiency caused by chronic diarrhea

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Administration of a pharmaceutical composition prepared by combining a muscarinic receptor antagonist with a phosphodiesterase (PDE-5) enzyme antagonist in a pharmaceutically acceptable carrier for the treatment of lower urinary tract syndrome (LUTS), hyperactive bladder, urinary incontinence, especially stress incontinence, urge incontinence, or mixed incontinence, lower urinary tract infection, urinary tract irritation and urinary tract irritation caused by drugs or chemicals or microorganisms, interstitial Cystitis and bladder pain syndrome with sexual dysfunction (such as impotence). Because the above two types of drugs all have a certain curative effect on lower urinary tract syndrome, the dosage of the above two types of drugs can be reduced in this pharmaceutical composition, so as to improve the curative effect and reduce the toxic and side effects.

Embodiment 2

[0043] The first pharmaceutical composition is prepared by combining a muscarinic receptor antagonist in a pharmaceutically acceptable carrier; by combining a phosphodiesterase (PDE-5) enzyme antagonist in a pharmaceutically acceptable carrier And prepare the second pharmaceutical composition. Administering the first composition to the patient once, twice, three, four, five, or six times per day; at the same time each day as the administration of the first composition or within 24 hours of administration of the first composition The second composition is administered to the same patient one, two, three, four, five or six times at any time. Alternatively, the second composition may be administered first, followed by administration of the first composition as disclosed simultaneously or within 24 hours of co-administration. This medication is prescribed for the treatment of lower urinary tract syndrome (LUTS), overactive bladder, urinary incontinence, especially stress incontin...

Embodiment 3

[0045] Prepare a pharmaceutical composition by combining a 5Alpha-reductase inhibitor with a phosphodiesterase (PDE-5) enzyme antagonist in a pharmaceutically acceptable carrier, and administer the composition to a patient for the treatment of lower urinary tract syndrome (LUTS) ), benign prostatic hyperplasia and other prostate diseases, accompanied by sexual dysfunction (such as impotence). Because the above two types of drugs all have a certain curative effect on lower urinary tract syndrome, the dosage of the above two types of drugs can be reduced in this pharmaceutical composition, so as to improve the curative effect and reduce the toxic and side effects.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of urogenital system and lower urinary tract diseases. The invention provides a new medicinal composition. The composition comprises medicinal effective compositionof the following substances: I) a first compound selected from medicaments for treating bladder hyperactivity such as muscarinic receptor antagonist and medicaments for treating prostate hyperplasia such as 5alpha-reductase inhibitor and alpha-adrenergic receptor antagonist, precursors thereof and pharmacologically acceptable salts thereof, II) a second compound selected from PDE-5 enzyme antagonist, precursor thereof and pharmacologically acceptable salt thereof, and III) a second compound selected from antidiuretic, precursor thereof and pharmacologically acceptable salt thereof, and optional pharmacologically acceptable vector thereof or diluent. The three medicaments can be combined two by two (such as I + II, or I + III, or II + III), or combined together at the same time (such as I +II + III). The invention also provides a group of methods for treating urogenital system and lower urinary tract diseases of mammals comprising people, wherein the methods comprise applying treatmenteffective dose of the composition to the mammals comprising people needing the treatment.

Description

technical field [0001] The invention relates to the field of genitourinary system and lower urinary tract diseases. It is based on the combined use of certain agonists and / or antagonists for the treatment of urinary diseases. [0002] The present invention provides a group of new pharmaceutical compositions, said compositions comprising the pharmaceutically effective combination of following substances: I) selected from the drugs for treating bladder hyperactivity such as muscarinic receptor antagonists and the drugs for treating benign prostatic hyperplasia such as 5α- Reductase inhibitors and □c-adrenergic receptor antagonists, their precursors and pharmaceutically acceptable salts of the first compound, and ll] selected from phosphodiesterase (PDE-5) enzyme antagonists, The second compound of their precursors and pharmaceutically acceptable salts, and 11] the second compound selected from antidiuretic (Antidiuretic), their precursors and pharmaceutically acceptable salts, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61P13/02A61P13/08A61P13/10
Inventor 许洁
Owner 许洁
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com